B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
Open Access
Abstract
Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies following talquetamab. The median follow‐up was 9.5 months (range: 6–24 months). The median progression free survival was 5.5 months (range: 1–10 months). Patients had varying grades of cytokine release syndrome and Immune effector cell‐associated neurotoxicity syndrome. Our results suggest that treatment with talquetamab followed by BCMA based therapies is feasible and can be considered as clinically indicated.Keywords
This publication has 8 references indexed in Scilit:
- Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current PerspectivesOncoTargets and Therapy, 2023
- Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myelomaBlood Advances, 2023
- Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsBlood, 2023
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaNew England Journal of Medicine, 2022
- Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple MyelomaBlood, 2021
- Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaLeukemia, 2021
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019